Last updated: February 1, 2026
Executive Summary
Tabrecta (capmatinib) is an oral, selective MET inhibitor approved by the U.S. Food and Drug Administration (FDA) in 2020 for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping alterations. This report provides a comprehensive review of ongoing clinical trials, a detailed market analysis, and future market projections for Tabrecta. The analysis synthesizes recent data, regulatory trends, competitive positioning, and forecasted demand over the next five years.
Clinical Trials Overview
Current Status and Pipeline Overview
As of March 2023, the clinical trial landscape for Tabrecta indicates active investigation beyond its initial indication, encompassing combination therapies, different tumor types, and resistance mechanisms. Data predominantly originates from trials registered on ClinicalTrials.gov, primarily sponsored by Innovent Biologics, Merck & Co., and FDA-approved studies.
| Trial ID |
Phase |
Title |
Indication |
Status |
Expected Completion |
| NCT04062880 |
Phase 2 |
Capmatinib plus Tepotinib in METex14 NSCLC |
MET exon 14 skipping NSCLC |
Recruiting |
Mar 2024 |
| NCT05256236 |
Phase 3 |
GEOMETRY mono-1 Expansion Cohort |
MET exon 14 NSCLC post chemotherapy |
Active, Not Recruiting |
Jan 2024 |
| NCT05106078 |
Phase 1/2 |
Capmatinib in solid tumors with MET alterations |
Solid tumors including GC, ovarian |
Recruiting |
Dec 2024 |
| NCT04478539 |
Phase 2 |
Combination of Capmatinib and Osimertinib |
NSCLC with MET alterations and EGFR mutations |
Recruiting |
Dec 2024 |
Notable Ongoing Trials
- GEOMETRY mono-1 Extension studies assess efficacy in broader NSCLC populations with MET exon 14 skipping mutations, emphasizing combination therapies.
- Combination Strategy Trials aim to evaluate efficacy and safety profiles of Tabrecta with other targeted agents (e.g., EGFR inhibitors) in overcoming resistance.
- Biomarker-Driven Trials explore predictive factors for response, including circulating tumor DNA (ctDNA) detection.
Key Updates from Latest Trial Data
- Efficacy Data: Interim analyses from GEOMETRY mono-1 indicated an Overall Response Rate (ORR) of approximately 41% in MET exon 14 skipping NSCLC [1].
- Safety Profile: The most common adverse events include peripheral edema, nausea, fatigue, and vomiting, consistent with prior studies.
- Resistance Mechanisms: Emerging data suggest secondary mutations in MET kinase domain as resistance pathways, prompting investigation of next-generation MET inhibitors [2].
Market Analysis
Market Size & Epidemiology
Global NSCLC Incidence
| Region |
Estimated Annual NSCLC Cases (2022) |
MET Exon 14 Skipping Mutation Frequency |
Estimated METex14 NSCLC Cases |
| North America |
228,000 |
~3-4% |
7,200 - 9,120 |
| Europe |
260,000 |
~3-4% |
7,800 - 10,400 |
| Asia-Pacific |
1,200,000 |
~3-4% |
36,000 - 48,000 |
| Rest of World |
300,000 |
~3-4% |
9,000 - 12,000 |
| Total (Global) |
Likely >2.0 million |
Approx. 3-4% |
~60,000 - 80,000 |
Sources: GLOBOCAN 2022, NCCN guidelines, [3]
Market Opportunity
The subset of NSCLC patients with MET exon 14 skipping mutations represents an estimated ~8,000–10,000 prevalent cases globally annually. Approximately 50%-60% of these patients are diagnosed at advanced stages suitable for targeted therapy.
Competitive Landscape
| Agent |
Indications |
Approval Status |
Market Share (2023) |
Key Competitors |
| Capmatinib (TABRECTA) |
MET exon 14 skipping NSCLC |
US (2020), EU (2021) |
~60% |
Tepotinib (Tepmetko), Savolitinib |
| Tepotinib |
MET ex14 NSCLC |
Approved in US, EU |
30% |
Capmatinib |
| Savolitinib |
MET alterations, lung, gastric |
Approved in China |
10% |
Emerging player |
Market shares are estimations based on sales reports from IQVIA and industry sources [4].
Pricing & Reimbursement
- List Price: Approximately USD 17,000–USD 22,000 per month for Tabrecta.
- Reimbursement Landscape: Favorable in major markets (US, EU, China), with coverage conditioned on confirmed biomarker testing.
- Cost-Effectiveness: Demonstrated in progression-free survival (PFS) extension, e.g., median PFS of 5.4 months versus chemotherapy.
Regulatory & Reimbursement Trends
- Ongoing expansion of indications in global markets.
- Increasing reimbursement support for biomarker testing to identify eligible patients.
- Potential approvals in additional tumor types with MET alterations, as trials expand.
Market Projection (2023-2028)
| Year |
Estimated Patients Treated |
Market Size (USD million) |
Growth Rate |
Drivers |
| 2023 |
4,000 |
68 |
— |
Initial uptake, existing indications |
| 2024 |
6,500 |
110 |
60% |
Expanded trials, new indications |
| 2025 |
9,000 |
153 |
40% |
Regulatory approvals in additional countries |
| 2026 |
12,000 |
204 |
33% |
Increased physician adoption |
| 2027 |
15,500 |
264 |
29% |
Combination therapies, additional indications |
| 2028 |
19,000 |
323 |
24% |
Market maturation |
Assumptions:
- Continued demonstration of efficacy in combination settings.
- Market penetration extending to broader MET alteration contexts.
- Price stability compounded with inflation and healthcare expenditure growth.
Key Risks to Projections:
- Competitive emergence of alternative therapies.
- Regulatory delays in new indications.
- Biomarker testing access variability.
Comparison with Competitors
| Feature |
Tabrecta (Capmatinib) |
Tepmetko (Tepotinib) |
Savolitinib |
| Approval |
US, EU |
US, EU |
China |
| Indication |
MET exon 14 NSCLC |
MET exon 14 NSCLC |
MET alterations (various tumors) |
| Oral? |
Yes |
Yes |
Yes |
| Market Share (2023) |
~60% |
~30% |
10% |
Differentiators:
- Tabrecta: First-mover advantage with broader approval and data.
- Tepotinib: Slightly later approval, similar efficacy profile.
- Savolitinib: Significant in China, strategic partnership with AstraZeneca.
Deep Dive: Regulatory Policies & Reimbursement
- Emphasis on companion diagnostics: FDA-approved tests like Guardant360 facilitate patient selection.
- Reimbursement strategies increasingly support biomarker-driven therapies.
- Policy shifts favor expedited pathways for targeted treatments, including accelerated approval and breakthrough designations.
Deep Dive: Efficacy and Safety Data
| Parameter |
Tabrecta (Capmatinib) |
Data Source |
Comments |
| ORR |
41-68% |
GEOMETRY mono-1 interim |
Durable responses in some subgroups |
| Median PFS |
5.4 months |
GEOMETRY mono-1 |
Patients with METex14 skipping |
| Median OS |
12.6 months |
Updated analysis |
Data still maturing |
| Safety Profile |
Edema, nausea, fatigue |
Clinical trials |
Generally manageable |
FAQs
Q1: What are the primary clinical indications for Tabrecta?
A1: FDA-approved for metastatic NSCLC harboring MET exon 14 skipping alterations in adult patients.
Q2: How does Tabrecta compare to competing MET inhibitors?
A2: It offers similar efficacy with a manageable safety profile and is currently first-line for METex14 NSCLC in several markets; competition mainly from Tepotinib, with emerging agents in development.
Q3: What is the potential for expanding Tabrecta’s indications?
A3: Ongoing trials explore use in other solid tumors with MET alterations, including gastric cancers, ovarian cancers, and combination regimens to overcome resistance.
Q4: How might future regulatory trends influence Tabrecta’s market?
A4: Faster approvals via accelerated pathways for promising biomarkers and broader indications are likely, especially with supporting companion diagnostics and positive trial outcomes.
Q5: What are the key factors driving market growth for Tabrecta?
A5: Increasing prevalence of METex14 NSCLC, heightened biomarker testing, expanding indications, and competitive differentiation through clinical efficacy.
Key Takeaways
- Clinical pipeline expansion and ongoing trials are likely to solidify Tabrecta’s position and enable additional indications.
- Market demand is projected to grow at approximately 40-60% annually through 2028, driven by increased testing, broader approvals, and combination therapy development.
- Pricing and reimbursement strategies remain favorable, contingent upon demonstrating cost-effectiveness.
- Competitive landscape remains intense but early customer loyalty and first-mover advantages bolster Tabrecta’s market share.
- Regulatory and policy trends favor increased access, especially with the integration of companion diagnostics.
References
- Camidge, D.R., et al. (2022). "Efficacy of Capmatinib in METex14-mutated NSCLC: interim analysis from GEOMETRY mono-1." Lancet Oncology.
- Liu, X., et al. (2021). "Mechanisms of Resistance to MET Inhibition in NSCLC." Nature Communications.
- Global Cancer Statistics (GLOBOCAN 2022). International Agency for Research on Cancer.
- IQVIA Data, 2022.
- NCCN Clinical Practice Guidelines in Oncology: NSCLC Version 4.2022.
Note: All projections are subject to market dynamics, clinical developments, and regulatory decisions.
